ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 159 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2020. The put-call ratio across all filers is 1.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $274,275 | -67.8% | 172,500 | +26.3% | 0.00% | -100.0% |
| Q4 2022 | $851,018 | +34.9% | 136,600 | +160.7% | 0.00% | – |
| Q3 2021 | $631,000 | -43.1% | 52,400 | 0.0% | 0.00% | -100.0% |
| Q2 2021 | $1,108,000 | -34.7% | 52,400 | -13.4% | 0.00% | 0.0% |
| Q1 2021 | $1,697,000 | +9.7% | 60,500 | +1.7% | 0.00% | 0.0% |
| Q4 2020 | $1,547,000 | -30.1% | 59,500 | 0.0% | 0.00% | -50.0% |
| Q3 2020 | $2,212,000 | -25.5% | 59,500 | +2.8% | 0.00% | -33.3% |
| Q2 2020 | $2,971,000 | +97.5% | 57,900 | +21.4% | 0.00% | +50.0% |
| Q1 2020 | $1,504,000 | -46.1% | 47,700 | +1.9% | 0.00% | -33.3% |
| Q4 2019 | $2,791,000 | +68.0% | 46,800 | +3.3% | 0.00% | +50.0% |
| Q3 2019 | $1,661,000 | -20.5% | 45,300 | +0.9% | 0.00% | 0.0% |
| Q2 2019 | $2,089,000 | +18.2% | 44,900 | +2.0% | 0.00% | 0.0% |
| Q1 2019 | $1,767,000 | -10.0% | 44,000 | +3.0% | 0.00% | -33.3% |
| Q4 2018 | $1,964,000 | +6.7% | 42,700 | +2.9% | 0.00% | +50.0% |
| Q3 2018 | $1,841,000 | +13.2% | 41,500 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $1,626,000 | -37.4% | 41,500 | +15.6% | 0.00% | -33.3% |
| Q1 2018 | $2,597,000 | +15.0% | 35,900 | +4.7% | 0.00% | +50.0% |
| Q4 2017 | $2,258,000 | +31.4% | 34,300 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $1,719,000 | +41.2% | 34,300 | +30.4% | 0.00% | +100.0% |
| Q2 2017 | $1,217,000 | +55.2% | 26,300 | +18.5% | 0.00% | 0.0% |
| Q1 2017 | $784,000 | +182.0% | 22,200 | 0.0% | 0.00% | – |
| Q4 2016 | $278,000 | -9.4% | 22,200 | 0.0% | 0.00% | – |
| Q3 2016 | $307,000 | +40.2% | 22,200 | 0.0% | 0.00% | – |
| Q2 2016 | $219,000 | -35.2% | 22,200 | +7.2% | 0.00% | -100.0% |
| Q1 2016 | $338,000 | -7.9% | 20,700 | +25.5% | 0.00% | 0.0% |
| Q4 2015 | $367,000 | -5.7% | 16,500 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $389,000 | -66.7% | 16,500 | +15.4% | 0.00% | -66.7% |
| Q2 2015 | $1,169,000 | -0.6% | 14,300 | +12.6% | 0.00% | 0.0% |
| Q1 2015 | $1,176,000 | +245.9% | 12,700 | +51.2% | 0.00% | +200.0% |
| Q4 2014 | $340,000 | – | 8,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |